Resonance Health Limited (ASX: RHT) has released an 'MRI Liver Fibrosis Device Progress & FY26 Portfolio Update' investor presentation. Investors are invited to join a live webinar on June 9th, 2026, to learn more about the company's progress. The webinar will be hosted by the Managing Director & CEO, Andrew Harrison, and Chief Scientific Officer, Dr Wenjie Pang.

The company's dedication to scientific rigour and quality has led to regulatory clearances for a range of Software-as-Medical-Devices (SaMDs) in the USA, Europe, UK, and Australia. Resonance Health's products have gained endorsement from leading physicians worldwide.

The development pipeline includes the MRI Liver Fibrosis Project, aimed at accurately assessing liver fibrosis progression using non-invasive MRI analysis. This presents a significant opportunity in the $40B+ liver diagnostics market.

Resonance Health's profitable platform, combined with the upcoming Liver Fibrosis device launch, positions the company for significant growth. The company's global reach, regulatory moat, and alignment with the GLP-1 trial boom highlight the potential for further expansion.

For further details and to participate in the webinar, please visit our website or contact Andrew Harrison, Managing Director, at andrewh@resonancehealth.com or +61 8 9286 5300. Invest in Resonance Health for a promising future in healthcare technology.